Скачать или смотреть Fanny Giannou (CEO & Founder, Alithea Bio) Explains HLA‑Compass for Precision Immunotherapy

In this short video, Fanny Giannou, founder and CEO of Alithea Bio, explains how the platform leverages advanced mass spectrometry, AI, and a unified bioinformatics pipeline to:
✅ Identify true immunotherapy targets
✅ Assess off-target toxicity
✅ Quantify HLA peptides across thousands of samples
✅ De-risk drug development pipelines

Alithea Bio’s mission: making cancer treatments safer, faster, and more effective through cutting-edge immunopeptidomics and innovative T-cell therapies.

✨ Learn how HLA-Compass supports biotech and pharma companies worldwide in developing next-generation cancer therapies.

👉 Visit our website to request a demo: www.alithea-bio.com
📍 Follow us on LinkedIn: https://www.linkedin.com/company/alithea-bio/

Instagram : https://www.instagram.com/alitheabio/

for the latest updates.

#Immunotherapy #HLAPeptides #CancerResearch #AIinHealthcare #MassSpectrometry #Biotechnology #PrecisionMedicine #HLACompass #AlitheaBio #TCRTherapy #Immunopeptidomics